Impact of autologous mitochondrial transfer on obstetric and neonatal health of offspring: A small single-center case series.

Autor: Gil J; Fundación IVI, Instituto de Investigación Sanitaria La Fe, 46026 Valencia Spain IVI-RMA Valencia, 46015 Valencia, Spain., Nohales M; Instituto Valenciano de Infertilidad (IVI), University of Valencia, Pl. Policía Local 3, Valencia, Spain., Ortega-Jaen D; Fundación IVI, Instituto de Investigación Sanitaria La Fe, 46026 Valencia Spain IVI-RMA Valencia, 46015 Valencia, Spain., Martin A; Fundación IVI, Instituto de Investigación Sanitaria La Fe, 46026 Valencia Spain IVI-RMA Valencia, 46015 Valencia, Spain., Pardiñas ML; Fundación IVI, Instituto de Investigación Sanitaria La Fe, 46026 Valencia Spain IVI-RMA Valencia, 46015 Valencia, Spain., Serra V; Instituto Valenciano de Infertilidad (IVI), University of Valencia, Pl. Policía Local 3, Valencia, Spain; Departamento de Pediatría, Obstetricia y Ginecología. University of Valencia, Avda. Blasco Ibañez 17, Valencia, Spain., Labarta E; Instituto Valenciano de Infertilidad (IVI), University of Valencia, Pl. Policía Local 3, Valencia, Spain., de Los Santos MJ; Fundación IVI, Instituto de Investigación Sanitaria La Fe, 46026 Valencia Spain IVI-RMA Valencia, 46015 Valencia, Spain; Instituto Valenciano de Infertilidad (IVI), University of Valencia, Pl. Policía Local 3, Valencia, Spain. Electronic address: Mariajose.DelosSantos@ivirma.com.
Jazyk: angličtina
Zdroj: Placenta [Placenta] 2024 Dec; Vol. 158, pp. 217-222. Date of Electronic Publication: 2024 Oct 15.
DOI: 10.1016/j.placenta.2024.10.007
Abstrakt: Introduction: A pilot study was carried out to test the efficacy of the autologous mitochondrial transfer therapy (AUGMENT) technique. No improvements in pregnancy rate, development, or embryo quality were observed in the AUGMENT-treated group versus the Control group in this study. The main objective of this research is to analyze whether AUGMENT technology did have any impact on the obstetric and perinatal outcomes of pregnancies and children resulting from treated oocytes.
Methods: Follow up study of women with a livebirth who participated in a pilot randomized controlled trial in which sibling MII oocytes were randomly allocated to AUGMENT + intracytoplasmic sperm injection (ICSI) (AUGMENT group) or ICSI alone (control group). Preimplantation genetic testing for aneuploidy was performed in both groups. Pregnancy and neonatal outcomes of 14 women (15 pregnancies) and their 18 children were analyzed. The information was retrieved by reviewing the medical records or through questionnaires sent to the patients.
Results: No differences were found in this small case series between the AUGMENT and control groups regarding the rate of gestational complications, birth defects, gestational age at delivery (271.4 ± 12.56 vs 278 ± 10.4 days), birthweight (3.1 ± 0.6 kg vs. 3.1 ± 0.4 kg) and neonatal outcome.
Discussion: The few pregnancies achieved using AUGMENT oocyte therapy had similar outcomes than controls in this very small series. Our very preliminary data need to be confirmed in larger samples. The long term follow up of these children also needs to be analyzed.
Competing Interests: Declaration of competing interest None.
(Copyright © 2024. Published by Elsevier Ltd.)
Databáze: MEDLINE
Externí odkaz: